Biosimilar User Fee Collections Drop Well Below Estimates, But US FDA Not Worried
Executive Summary
The agency hopes application volume increases, but warns the biosimilar user fee revenue will remain volatile.
You may also be interested in...
US FDA Making BsUFA III Regulatory Science Grants Available Early
Up to $1m per year per award is available for projects that address significant issues with biosimilar or interchangeable product development.
US FDA Making BsUFA III Regulatory Science Grants Available Early
Up to $1m per year per award is available for projects that address significant issues with biosimilar or interchangeable product development.
FY 2019 Drug Development Drives FY 2021 User Fees Lower
Biosimilar development programs also are expected to increase, a promising sign for the growing sector, but those fees remained unchanged.